Biomarkers /
CCDC6
Overview
CCDC6 is altered in 0.27% of all cancers with lung adenocarcinoma, thyroid gland papillary carcinoma, breast invasive ductal carcinoma, adenocarcinoma of the gastroesophageal junction, and cholangiocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CCDC6 are CCDC6-RET Fusion (0.14%), CCDC6-BRAF Fusion (0.10%), CCDC6-ROS1 Fusion (0.05%), CCDC6-FGFR2 Fusion (0.01%), and CCDC6-WAS Fusion (0.02%) [3].
Clinical Trials
Significance of CCDC6 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.